Fortress Biotech, Inc. FBIO
At closeNov 5, 2026, 4:00 PM EST
After hours · Nov 5, 4:00 PM ET
- YTD
- -49.73%
- 1 year
- -25.81%
- Market cap
- 61.37M
- Revenue (ttm)
- 82.62M
- Profit margin
- -49.25%
- EPS (ttm)
- 2.76
- Shares out
- 27.60M
- P/E ratio
- 0.67
- Forward P/E
- -0.99
- YTD return
- -49.73%
- 1-year return
- -25.81%
- Volume
- 306.86K
- Avg volume
- 342.49K
- Open
- 1.98
- Previous close
- 1.97
- Day's range
- 1.79 – 1.98
- 52-week range
- 1.79 – 4.53
- Beta
- 1.75
- Price target
- 14.33 (+679.0%)
5D -0.17 (-8.46%)
Key statistics
- Enterprise value
- 12.37M
- PEG ratio
- 0.00
- Price / sales
- 0.58
- Price / book
- 1.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -14.30%
- Free cash flow
- -59.20M
- Total cash
- 76.20M
- Total debt
- 88.42M
- Return on equity
- 0.00%
- Short % of float
- 11.50%
- 50-day average
- 1.83
- 200-day average
- 1.84
Analyst view
- Target (low)
- 4.00
- Target (mean)
- 14.33
- Target (high)
- 24.00
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.27 | -0.76 | -0.49 | -181.48% |
| Aug 13, 2024 | Jun 1, 2024 | -1.32 | -0.73 | +0.59 | +44.70% |
| May 15, 2024 | Mar 1, 2024 | -2.03 | -1.03 | +1.00 | +49.26% |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -0.53 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -3.53 | -0.94 | +2.59 | +73.37% |
| Aug 14, 2023 | Jun 1, 2023 | -3.90 | -3.60 | +0.30 | +7.69% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 20, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| May 16, 2024 | Roth MKM | reit | Buy | Buy |
| Mar 19, 2024 | Alliance Global Partners | init | — | Buy |
| Nov 29, 2023 | Roth MKM | main | Buy | Buy |
About Fortress Biotech, Inc.
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fortressbiotech.com
News
Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
12 Health Care Stocks Moving In Monday's Intraday Session Fortress Biotech’s Urica Therapeutics Says Crystalys Closes Oversubscribed $130M Series B Financing To Support Late-Stage Global Clinical Development And Commercialization Preparation For Dotinurad
Fortress Biotech Q1 EPS $2.82 Beats $(0.22) Estimate, Sales $16.038M Miss $16.338M Estimate
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket
Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket 12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
Your note
Sign in to keep a note on FBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HARVEY JIMMIE | Director | Stock Award(Grant) | Dec 28, 2023 | 69,999 |
| HOENLEIN MALCOLM | Director | Stock Award(Grant) | Dec 28, 2023 | 39,042 |
| JIN DAVID | Chief Financial Officer | Stock Award(Grant) | Sep 30, 2024 | 240,893 |
| KLEIN DOV | Director | Sale | May 19, 2024 | 53,400 |
| LOBELL JONAH JAY | Director | Stock Award(Grant) | Dec 28, 2023 | 115,692 |
| LORENZ KEVIN R. | Director | Stock Award(Grant) | Dec 28, 2023 | 24,970 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.26% | 625,054 | 1.09M | Sep 29, 2024 |
| Cambridge Investment Research Advisors Inc. | 2.01% | 554,400 | 964.66K | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 1.82% | 502,828 | 874.92K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 1.75% | 482,595 | 839.72K | Sep 29, 2024 |
| Shikiar Asset Management, Inc. | 0.85% | 235,969 | 410.59K | Sep 29, 2024 |
| Envestnet Asset Management | 0.67% | 183,946 | 320.07K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.70% | 470,544 | 818.75K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.55% | 152,474 | 265.30K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 95,862 | 166.80K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.12% | 33,086 | 57.57K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 29,297 | 50.98K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 22,655 | 39.42K | Oct 30, 2024 |
